Investor Presentation First Nine Months of 2022

108 Investor presentation First nine months of 2022 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets 14% >487m live with diabetes 10% >600m live with obesity 6% 5% IO's share of revenue FY 2021 2% NAO 48% ΙΟ 52% Historic growth has been in the range of 4-8% 14% 30% Growth momentum in IO Novo NordiskⓇ 26% 21% 20% 14% 10% 0% Aug 2014 2021 2019 Growth rate range NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year Source (RHS): IQVIA Aug 2022, Value, MAT NN Diabetes market share Market growth NN Diabetes growth Aug 2022

View entire presentation